Table IV.
Parameters Estimated Using the PK/PD/DIS Arthritis Progression Model Presented in Fig. 1b Following Multiple Administration of GRMS-55, (±)-LSF, or Rolipram to Rats with Experimentally Induced Arthritis
| (±)-LSF | GRMS-55 | Rolipram | ||
|---|---|---|---|---|
| Parameter | Brief description | Final estimate (CV%) | Final estimate (CV%) | |
| kout (day-1) | Degradation of precursor rate constant | 0.258 (1.7) | 0.281 (1.6) | |
| kdeg (day-1) | Loss of production rate constant | 0.0133 (13.4) | 0.0127 (15.4) | |
| tonset (day) | Time of disease onset | 12.6 (3.9) | 13.3 (2.3) | |
| τ (day) | Mean transit time | 0.371 (19.7) | 0.257 (16.8) | |
| IC50 (mg L-1) | Concentration producing 50% of maximal inhibition | 1.06 (77.3) | 0.26 (45.0) | 0.01 (75.5) |
| kgrow (day-1) | Natural growth rate constant | 0.004a | 0.004a | 0.004a |
| kin(0) (day-1) | Initial value of precursor production variable | 0.498 (1.1) | 0.521 (1.5) | 0.523 (1.2) |
| Imax | Maximal inhibitory potency | 1b | 1b | 1b |
acalculated based on the data from (22); b fixed during fitting procedure